1. Home
  2. Stocks
  3. Torntpharm Share Price
  • Chart
  • F&O
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs

    • Torrent Pharmaceuticals Share Price

    Large Cap
    ₹3,461.45
    + 25.9 (0.75%)
    • Advice
    • Hold
    12 September, 2024 18:58 BSE: 500420 NSE: TORNTPHARM ISIN: INE685A01028
    Bonus

    Start SIP in Torrent Pharmaceuticals

    Start SIP

    Torrent Pharmaceuticals Performance

    Day Range

    • Low 3,450
    • High 3,525
    ₹ 3,461

    52 Week Range

    • Low 1,821
    • High 3,574
    ₹ 3,461
    • Open Price3,460
    • Previous Close3,436
    • Volume388926

    Torrent Pharmaceuticals Chart

    • Over 1 Month + 3.69%
    • Over 3 Month + 21.41%
    • Over 6 Month + 28.31%
    • Over 1 Year + 85.38%

    Torrent Pharmaceuticals Key Statistics

    P/E Ratio 67.5
    PEG Ratio 1.8
    Market Cap Cr
    Price to Book Ratio 17.1
    EPS 39.7
    Dividend 0.8
    Relative Strength Index 65.95
    Money Flow Index 73.46
    MACD Signal 71.63
    Average True Range 78.26

    Torrent Pharmaceuticals F&O

    Torrent Pharmaceuticals Futures Torrent Pharmaceuticals Option Chain

    Torrent Pharmaceuticals Investment Rating

    • Master Rating:

    • Torrent Pharmaceuticals has an operating revenue of Rs. 10,996.00 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 22% is great, ROE of 24% is exceptional. The company has a reasonable debt to equity of 23%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 7% and 26% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 81 which is a GOOD score indicating consistency in earnings, a RS Rating of 70 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 54 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Torrent Pharmaceuticals Financials
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 2,3942,1432,1232,1462,1211,920
    Operating Expenses Qtr Cr 1,5391,4271,4221,4101,3841,342
    Operating Profit Qtr Cr 899716701736737578
    Depreciation Qtr Cr 189195191192183182
    Interest Qtr Cr 646769779094
    Tax Qtr Cr 198120133155152109
    Net Profit Qtr Cr 469410297327323219
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 8,6247,777
    Operating Expenses Annual Cr 5,6445,230
    Operating Profit Annual in Cr 2,8892,465
    Depreciation Cr 761672
    Interest Annual Cr 303298
    Tax Annual Cr 559526
    Net Profit Annual Cr 1,3571,051
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 2,8932,265
    Cash from Investing Activity Annual Cr -296-2,384
    Cash from Financing Annual Activity Cr -2,57881
    Net Cash Flow Annual Cr 19-38
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 6,8296,456
    Fixed Assets Annual Cr 8,2128,670
    Total Non Current Assets Annual Cr 8,6368,945
    Total Current Assets Annual Cr 3,7413,927
    Total Assets Annual Cr 12,37712,872
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 202191
    ROE Annual % 2016
    ROCE Annual % 2420
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3533
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 2,8152,7452,7322,6602,5912,491
    Operating Expenses Qtr Cr 1,9551,8621,8631,8351,8001,764
    Operating Profit Qtr Cr 904883869825791727
    Depreciation Qtr Cr 197203213201191196
    Interest Qtr Cr 75808091103107
    Tax Qtr Cr 199182188173153146
    Net Profit Qtr Cr 457449443386378287
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 10,7869,665
    Operating Expenses Annual Cr 7,3606,778
    Operating Profit Annual in Cr 3,3682,842
    Depreciation Cr 808707
    Interest Annual Cr 354333
    Tax Annual Cr 696602
    Net Profit Annual Cr 1,6561,245
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 3,2662,368
    Cash from Investing Activity Annual Cr -168-2,415
    Cash from Financing Annual Activity Cr -2,78077
    Net Cash Flow Annual Cr 31930
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 6,8566,198
    Fixed Assets Annual Cr 8,1618,549
    Total Non Current Assets Annual Cr 9,4499,683
    Total Current Assets Annual Cr 5,6115,329
    Total Assets Annual Cr 15,06115,012
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 203183
    ROE Annual % 2420
    ROCE Annual % 2723
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3230
    Invest in Torrent Pharmaceuticals

    Torrent Pharmaceuticals Technicals

    EMA & SMA

    Current Price
    ₹3,461.45
    + 25.9 (0.75%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹3,393.49
    • 50 Day
    • ₹3,241.92
    • 100 Day
    • ₹3,041.71
    • 200 Day
    • ₹2,760.34
    • 20 Day
    • ₹3,404.94
    • 50 Day
    • ₹3,225.01
    • 100 Day
    • ₹2,975.97
    • 200 Day
    • ₹2,714.06

    Torrent Pharmaceuticals Resistance and Support

    PIVOT
    ₹3,478.92
    Resistance
    First Resistance 3,507.53
    Second Resistance 3,553.62
    Third Resistance 3,582.23
    RSI 65.95
    MFI 73.46
    MACD Single Line 71.63
    MACD 61.18
    Support
    First Support 3,432.83
    Second Support 3,404.22
    Third Supoort 3,358.13

    Torrent Pharmaceuticals Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 393,871 18,279,553 46.41
    Week 250,262 13,539,185 54.1
    1 Month 277,164 14,584,360 52.62
    6 Month 291,944 15,624,859 53.52

    Torrent Pharmaceuticals Result Highlights

    Torrent Pharmaceuticals Synopsis

    NSE-Medical-Generic Drugs

    Torrent Pharmac is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 8532.90 Cr. and Equity Capital is Rs. 169.23 Cr. for the Year ended 31/03/2024. Torrent Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 15/07/1972 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1972PLC002126 and registration number is 002126.
    Market Cap 116,274
    Sales 8,850
    Shares in Float 9.81
    No of funds 790
    Yield 0.82
    Book Value 17.03
    U/D Vol ratio 3
    LTDebt / Equity 23
    Alpha 0.21
    Beta 0.43

    Torrent Pharmaceuticals Shareholding Pattern

    Owner NameJun-24Mar-24Dec-23Sep-23
    Promoters 71.25%71.25%71.25%71.25%
    Mutual Funds 4.35%4.46%4.48%5.32%
    Insurance Companies 2%1.95%1.96%1.85%
    Foreign Portfolio Investors 14.22%14.14%14.08%13.15%
    Financial Institutions/ Banks 0.01%
    Individual Investors 3.98%4.08%4.15%4.25%
    Others 4.19%4.12%4.08%4.18%

    Torrent Pharmaceuticals Management

    Name Designation
    Mr. Sudhir Mehta Chairman Emeritus
    Mr. Samir Mehta Executive Chairman
    Mr. Aman Samir Mehta Whole Time Director
    Mr. Jinesh Shah Director - Operations
    Mr. Jinal Mehta Non Executive Director
    Mr. Manish Mahendra Choksi Independent Director
    Dr. Maurice Chagnaud Independent Director
    Mr. Nikhil Khattau Independent Director
    Ms. Ameera Shah Independent Director
    Ms. Nayantara Bali Independent Director

    Torrent Pharmaceuticals Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Torrent Pharmaceuticals Corporate Action

    Date Purpose Remarks
    2024-07-23 Quarterly Results
    2024-05-24 Audited Results & Final Dividend
    2024-02-02 Quarterly Results & Interim Dividend
    2023-10-23 Quarterly Results
    2023-08-07 Quarterly Results
    Date Purpose Remarks
    2024-06-21 FINAL Rs.6.00 per share(120%)Final Dividend
    2024-02-12 INTERIM Rs.22.00 per share(440%)Interim Dividend
    2023-06-23 FINAL Rs.8.00 per share(160%)Final Dividend
    2023-02-03 INTERIM Rs.14.00 per share(280%)Interim Dividend
    2022-06-06 FINAL Rs.8.00 per share(160%)Final Dividend
    Date Purpose Remarks
    2022-07-11 Bonus Rs.0.00 issue of equity shares in the ratio of 1:1 of Rs. 5/-.

    Torrent Pharmaceuticals MF Shareholding

    Name Amount(cr)
    Kotak Equity Arbitrage Fund Growth 51,570
    Kotak Emerging Equity Scheme Growth 50,602
    Mirae Asset Large Cap Fund Regular Growth 41,352
    SBI Arbitrage Opportunities Fund Regular Growth 32,415
    Axis Midcap Fund Growth 30,855

    About Torrent Pharmaceuticals

    Torrent Pharmaceuticals Limited (TPL) is one of India’s leading pharmaceutical companies, with a strong presence in research and development, manufacturing and marketing. In terms of oncology specialty therapies, TPL is one of India's leading pharma companies. The specialties business includes three major therapeutic areas: Cancer Chemotherapy, Cardiology, and Anti-Infectives. TPL has established itself as a leader in its field by providing affordable medicines to patients across India. In addition to cancer care, TPL is also recognized for its anti-infective products, such as Ciprofloxacin which are widely used in treating bacterial infections. 

    Business Verticals

    Torrent Pharmaceuticals is a global specialty pharmaceutical and OTC medicines player. The Company has two divisions: Pharmaceuticals and Consumer Healthcare (OTC). 

    Torrent's Pharmaceuticals division consists of three major therapeutic areas: Cardiovascular, Central Nervous System (CNS) and Metabolic Diseases. Its products include branded formulations for treating cardiovascular diseases, central nervous system disorders and metabolic diseases. They are available as tablets, capsules, injectables and syrups. 

    It also offers active pharmaceutical ingredients (APIs), which other companies use to manufacture their drugs. In addition, Torrent's Pharmaceuticals markets its consumer healthcare products through its direct sales force in India. Torrent has manufacturing facilities across India and exports its products to over 80 countries worldwide.

    Milestones

    1959 - Shri U. N. Mehta ventured in the pharmaceutical  industry.

    1971 - Trinity Laboratories was renamed as Torrent Pharmaceuticals Limited.

    1980 - The first manufacturing facility was established in Ahmedabad at Vatva.

    1983 - Torrent Pharmaceuticals enters international markets with the first export order to the USSR.

    1984
    Torrent Laboratories Limited wins Chemexcil Export Award.
    Torrent Laboratories Limited received the Udyog Ratna Award.

    1985
    After demonstrating exceptional export performance, Torrent Laboratories Limited is honoured with the IMC Golden Jubilee Endowment Award.
    Torrent Exports Limited wins the Gujarat Government export award.
    IDMA awarded Torrent Laboratories Limited the Quality Excellence Award.

    1986
    Torrent Laboratories Limited wins the Chemexcil Export Award third time in a row.
    The IDMA Quality Excellence Award was presented to Torrent Laboratories Limited.
    Torrent Exports Limited wins the Gujarat Government export award again.

    1987
    Torrent Laboratories Limited wins the Chemexcil Export Award for the fourth consecutive year.
    The Gujarat government awarded Torrent Exports Limited an export award for the third time.

    1988 - Torrent Laboratories Limited wins the Chemexcil Export Award for the fifth consecutive year.

    1989
    Torrent Laboratories establish their second manufacturing plant.
    Chemexcil Trishul Award for Highest Pharma Exports awarded to Torrent Exports Limited.
    Torrent Pharmaceuticals Limited wins the IDMA Quality Excellence Award.

    1990
    Torrent Exports Limited wins the National Export Award.
    Torrent Pharmaceuticals Ltd wins the International Friendship's Pride of Asia International award for excellence in pharmaceutical products.

    1992 - Torrent Pharmaceuticals Limited wins the IDMA Quality Excellence Award for the second time.

    1995 - The Torrent Gujarat Biotech Limited plant gets commissioned.

    1999
    Torrent Pharmaceuticals Ltd gets revamped. Three new divisions, Prima, Vista, and Psycan, are formed.
    Torrent Research Center receives its first patent for a new chemical entity.
    Torrent Exports Limited wins the GCCI Export Recognition Award
    Torrent Pharma wins the IDMA Gold Trophy.

    2000
    Torrent Research Center is awarded the OECD Standards of Good Laboratory Practices Certificate by the Dutch Health Ministry.
    The Indrad Plant gets the ISO 9001:2000 certification.

    2001
    In terms of Return on Capital Employed, Torrent Pharma was ranked among the top ten Indian companies (ET - BCG Study Feb - 2001).
    Torrent Pharmaceuticals wins the 'Best Suppliers' award by the Sri Lankan State Pharmaceutical Corporation.
    Torrent Pharma wins the IDMA Quality Excellence Award Gold Trophy for its Formulation facility. It is awarded the Silver Trophy for its API manufacturing facility as well.
    Torrent do Brasil Ltda. was founded and incorporated in Brazil.

    2002
    The AGE (Advanced Glycosylation End-products) molecule is discovered and patented.
    Torrent Pharma's Indrad Plant gets ISO 14001:1996 and OHSAS 18001:1999 certifications.
    Torrent's R&D Center with ISO/IEC 17025:1999 gets accredited by the National Accreditation Board for Testing and Calibration Laboratories for its facilities (NABL).
    Torrent Pharmaceuticals Ltd launches a new marketing division, MIND.
    Torrent Research Center develops its own Dual Retard Inlay Technology, Compact Tablet Technology, Gastro Retentive System, and Multiparticulate / Matrix Based SR / Modified Release Formulations.

    2003
    Torrent Pharma Inc. is founded and incorporated in the United States.
    Torrent Pharmaceuticals Manufacturing Plant receives GMP certification from the European Union.
    Torrent Pharma Philippines Inc. is founded and incorporated.
    Torrent Pharma received the Gold Trophy for the IDMA Quality Excellence Award again for its formulation and API manufacturing facilities.

    2006
    The API and formulation manufacturing facilities in Indrad (Gujarat, India) receive the most coveted US FDA approval.
    South African Torrent Pharma and Pharma Dynamics (Pty) Ltd signed a Technical Agreement to supply various products.

    2007
    Indrad Plant with ISO 9001: 2000 (Quality Management System), ISO 14001:2004 (Environmental Management System), and OHSAS 180001:1999 (Occupational Health and Safety Management System) get certified by ISOQAR, a UKAS accredited body.
    Sikkim Plant construction begins.

    2008 - The Baddi Plant gets the prestigious GMP certification from the Government of Upper Bavaria in Germany.

    2009
    Novo Nordisk commissions a dedicated formulation and packaging unit to Torrent Pharmaceuticals Ltd for exclusively manufacturing Insulin.
    AstraZeneca signed a license and supply agreement to market its products in the international market.
    Baddi Plant gets a five-star rating from the British Safety Council.

    2010
    Baddi Plant receives the OHSAS Audit 18001:2007 certification. Uganda's regulatory authority approves the Baddi Plant facility.
    An advanced facility for Stability Studies gets established at the Indrad Plant.
    Torrent Pharmaceuticals Ltd enter the field of gynaecology therapy.
    Laboratories Torrent S.A. de C.V Mexico begins its commercial operations.
    Dahej manufacturing facility construction begins.

    2011
    The Sikkim Plant begins operations.
    Torrent Research Center creates an indigenous nasal drug delivery system.
    Torrent Pharmaceuticals Ltd launches Sparsh, a dedicated division to serve the Dermatology Segment.

    2012
    The Indrad Plant is bestowed with the Sword of Honor for Occupational Health and Safety by the British Safety Council.
    Torrent Research Center discovers the Topical Foams system.

    2013 - Torrent Pharma signs a licensing agreement with Reliance Life Sciences for three biosimilars: rituximab, adalimumab, and cetuximab.

    2014
    Elder Pharma's identified Indian Branded Formulation Business in India and Nepal gets acquired by Torrent Pharmaceuticals. 
    Nephro, a dedicated division is established to exclusively serve the Nephrology Segment.
    The Dahej Plant of Torrent Pharma initiates their operations.

    2015
    10th CNBC TV18 India Business Leader Awards 2014 witnesses the victory of Torrent Pharma as the Most Promising Company of the Year.
    Torrent acquired Zyg Pharma.

    2016
    The Dahej Plant gets the USFDA certification.
    Torrent Pharmaceuticals acquires API manufacturing unit of Hyderabad-based Glochem Industries Limited.

    2017
    Torrent Pharmaceuticals acquire Unichem's domestic and Nepal operations along with its Sikkim manufacturing facility.
    Business World Magazine names them as one of the top five 'Fastest Growing Companies (Middleweights Category)'.
    Executive Chairman, is named as one of India's Most Valuable CEOs in the by Business World Magazine.
    Torrent Pharmaceuticals acquires all Novartis' Women Healthcare brands.

    2018 - Torrent makes its first overseas purchase by acquiring Bio-Pharm Inc. (BPI), based in the United States along with a US FDA-registered manufacturing facility. 

    2019 - Torrent and Glenmark sign a licensing agreement for co-marketing Remogliflozin Etabonate pan-India.

    2021
    In India, Torrent Pharma launches MSD (a trademark of Merck & Co., Inc, Kenilworth, NJ, USA) and Ridgeback's Molnupiravir under the brand name Molnutor®.
    Torrent Pharma Signs Voluntary Licensing Agreement with Lilly to produce and distribute Baricitinib for Covid-19 in India.

    2022 
    Torrent finalizes the acquisition of Dr. Reddy's Laboratories Ltd. four brands: "Styptovit-E," "Finast," "Finast-T," and "Dynapress."
    Torrent Pharma signs a licensing agreement with Medicine Patent Pool for the production and marketing of a generic version of Pfizer's Oral COVID-19 Treatment.

    Torrent Pharmaceuticals FAQs

    What is Share Price of Torrent Pharmaceuticals ?

    Torrent Pharmaceuticals share price is ₹3,461 As on 12 September, 2024 | 18:44

    What is the Market Cap of Torrent Pharmaceuticals ?

    The Market Cap of Torrent Pharmaceuticals is ₹117151.2 Cr As on 12 September, 2024 | 18:44

    What is the P/E ratio of Torrent Pharmaceuticals ?

    The P/E ratio of Torrent Pharmaceuticals is 67.5 As on 12 September, 2024 | 18:44

    What is the PB ratio of Torrent Pharmaceuticals ?

    The PB ratio of Torrent Pharmaceuticals is 17.1 As on 12 September, 2024 | 18:44

    What were the company's most recent reported sales and net income?

    Torrent Pharmaceuticals Ltd recorded a net sales of INR 8508 crores in the year ending March 2022.

    What is the future of the company's shares?

    Torrent Pharmaceuticals Ltd stock is a good option for long-term investment since the stock prices indicate a strong buying trend.

    How to buy shares of Torrent Pharmaceuticals Ltd.?

    The company's shares can be bought online by opening a demat account with 5paisa and verifying the KYC documents. You can also use our mobile app for a fast experience.

    Q2FY23
    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     
    footer_form

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of ₹10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5Paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.